NCT00457509View on ClinicalTrials.gov

Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

September 30, 2010

Conditions
Pandemic InfluenzaInfluenza A Virus InfectionOrthomyxoviridae Infections
Interventions
BIOLOGICAL

A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant

0.5 mL, Intramuscular

BIOLOGICAL

A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant

0.5 mL, Intramuscular

BIOLOGICAL

A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant

0.5 mL, Intramuscular

BIOLOGICAL

A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant

0.5 mL, Intramuscular

BIOLOGICAL

A/H5N1 inactivated, split-virion influenza vaccine

0.5 mL, Intramuscular

Trial Locations (3)

Unknown

Brussels

Ghent

Leuven

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00457509 - Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter